Cargando…
Programmed Cell Death after Intracerebral Hemorrhage
BACKGROUND: Intracerebral hemorrhage (ICH) accounts for up to 15% of all strokes and is characterized by high rates of mortality and morbidity. The post-ICH brain injury can be distinguished in 1) primary, which are caused by disrup-tion and mechanical deformation of brain tissue due to hematoma gro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251052/ https://www.ncbi.nlm.nih.gov/pubmed/28571544 http://dx.doi.org/10.2174/1570159X15666170602112851 |
_version_ | 1783373035507548160 |
---|---|
author | Bobinger, Tobias Burkardt, Petra Huttner, Hagen B. Manaenko, Anatol |
author_facet | Bobinger, Tobias Burkardt, Petra Huttner, Hagen B. Manaenko, Anatol |
author_sort | Bobinger, Tobias |
collection | PubMed |
description | BACKGROUND: Intracerebral hemorrhage (ICH) accounts for up to 15% of all strokes and is characterized by high rates of mortality and morbidity. The post-ICH brain injury can be distinguished in 1) primary, which are caused by disrup-tion and mechanical deformation of brain tissue due to hematoma growth and 2) secondary, which are induced by microglia activation, mitochondrial dysfunction, neurotransmitter and inflammatory mediator release. Although these events typically lead to necrosis, the occurrence of programmed cell death has also been reported after ICH. METHODS: We reviewed recent publications describing advance in pre- and clinic ICH research. RESULTS: At present, treatment of ICH patients is based on oral anticoagulant reversal, management of blood pressure and other medical complications. Several pre-clinical studies showed promising results and demonstrated that anti-oxidative and anti-inflammatory treatments reduced neuronal cell death, however, to date, all of these attempts have failed in randomized controlled clinical trials. Yet, the time frame of administration may be crucial in translation from animal to clinical studies. Furthermore, the latest pre-clinical research points toward the existence of other, apoptosis-unrelated forms kinds of pro-grammed cell death. CONCLUSION: Our review summarizes current knowledge of pathways leading to programmed cell death after ICH in addition to data from clinical trials. Some of the pre-clinical results have not yet demonstrated clinical confirmation, however they sig-nificantly contribute to our understanding of post-ICH pathology and can contribute to development of new therapeutic ap-proaches, decreasing mortality and improving ICH patients’ quality of life. |
format | Online Article Text |
id | pubmed-6251052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-62510522019-05-01 Programmed Cell Death after Intracerebral Hemorrhage Bobinger, Tobias Burkardt, Petra Huttner, Hagen B. Manaenko, Anatol Curr Neuropharmacol Article BACKGROUND: Intracerebral hemorrhage (ICH) accounts for up to 15% of all strokes and is characterized by high rates of mortality and morbidity. The post-ICH brain injury can be distinguished in 1) primary, which are caused by disrup-tion and mechanical deformation of brain tissue due to hematoma growth and 2) secondary, which are induced by microglia activation, mitochondrial dysfunction, neurotransmitter and inflammatory mediator release. Although these events typically lead to necrosis, the occurrence of programmed cell death has also been reported after ICH. METHODS: We reviewed recent publications describing advance in pre- and clinic ICH research. RESULTS: At present, treatment of ICH patients is based on oral anticoagulant reversal, management of blood pressure and other medical complications. Several pre-clinical studies showed promising results and demonstrated that anti-oxidative and anti-inflammatory treatments reduced neuronal cell death, however, to date, all of these attempts have failed in randomized controlled clinical trials. Yet, the time frame of administration may be crucial in translation from animal to clinical studies. Furthermore, the latest pre-clinical research points toward the existence of other, apoptosis-unrelated forms kinds of pro-grammed cell death. CONCLUSION: Our review summarizes current knowledge of pathways leading to programmed cell death after ICH in addition to data from clinical trials. Some of the pre-clinical results have not yet demonstrated clinical confirmation, however they sig-nificantly contribute to our understanding of post-ICH pathology and can contribute to development of new therapeutic ap-proaches, decreasing mortality and improving ICH patients’ quality of life. Bentham Science Publishers 2018-11 2018-11 /pmc/articles/PMC6251052/ /pubmed/28571544 http://dx.doi.org/10.2174/1570159X15666170602112851 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Bobinger, Tobias Burkardt, Petra Huttner, Hagen B. Manaenko, Anatol Programmed Cell Death after Intracerebral Hemorrhage |
title | Programmed Cell Death after Intracerebral Hemorrhage |
title_full | Programmed Cell Death after Intracerebral Hemorrhage |
title_fullStr | Programmed Cell Death after Intracerebral Hemorrhage |
title_full_unstemmed | Programmed Cell Death after Intracerebral Hemorrhage |
title_short | Programmed Cell Death after Intracerebral Hemorrhage |
title_sort | programmed cell death after intracerebral hemorrhage |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251052/ https://www.ncbi.nlm.nih.gov/pubmed/28571544 http://dx.doi.org/10.2174/1570159X15666170602112851 |
work_keys_str_mv | AT bobingertobias programmedcelldeathafterintracerebralhemorrhage AT burkardtpetra programmedcelldeathafterintracerebralhemorrhage AT huttnerhagenb programmedcelldeathafterintracerebralhemorrhage AT manaenkoanatol programmedcelldeathafterintracerebralhemorrhage |